



**Vita Life Sciences Limited**  
**Appendix 4D**  
**For the half year ended 30 June 2013**

**To :** Company Announcements

---

**Company:** Australian Securities Exchange Fax No.:

---

**Date:** 26 August 2013 No. of pages 24 incl. cover

---

**From:** Ernest Chunge Fax No.:

---

**Subject :** **Appendix 4D**

---

Please see attached 30 June 2013 Half Yearly Report for Vita Life Sciences Limited (ASX - VSC).

This announcement is made pursuant to Listing rule 4.2A.3. For all enquiries please contact

Mr Ernest Chunge  
Company Secretary  
Vita Life Sciences Limited

Telephone 02 9545 2633

Fax 02 9545 1311

## 1. Company details

### Name of entity

<b>VITA LIFE SCIENCES LIMITED</b>
-----------------------------------

### ABN or equivalent company reference

35 003 190 421
----------------

### Half year ended ('current period')

30 June 2013
--------------

### Half year ended ('previous period')

30 June 2012
--------------

The information contained in this report is to be read in conjunction with Vita Life Sciences Limited's 2012 Annual Report and any announcements to the market by Vita Life Sciences Limited during the half year ended 30 June 2013.

## 2. Results for announcement to the market

		Percentage Change %	2013 A\$'000
<b>2.1</b>	<b>Revenue</b>	up 18.5	17,083
	<b>Profit before income tax</b>	up 130.9	2,538
<b>2.2</b>	<b>Net profit after tax</b>	up 117.6	2,146
<b>2.3</b>	<b>Net profit attributable to members</b>	up 115.1	2,136

<b>2.4</b>	<b>Dividends (distributions)</b>		<b>Amount per security</b>	<b>Franked amount per security</b>
<b>2.5</b>	Interim 2013 dividend	Record Date To Be Paid	22 September 2013 29 September 2013	1.0 cents 0.41 cents
	Final 2012 dividend	Record Date Paid	15 March 2013 28 March 2013	0.5 cents 0.5 cents

**2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable the figures to be understood.**

The Board of Directors is pleased to announce Vita Life Sciences Limited's ("Group") revenue was \$17.083m (2012: \$14.407m) with an EBIT margin of 14.9% (2012: 7.7%) resulting in a profit after tax of \$2.146m for the half year to 30 June 2013 (2012: \$0.986m).

Revenue was driven by the continued growth from the Established Business Units in Australia, Malaysia and Singapore, with total sales of \$14.758m (2012: \$12.768m), an increase of 15.6%. Due to economies of scale resulting from the higher sales recorded, EBIT margins increased across the 3 countries when measured against the six months to June 2012.

The Group's New Business Units (Thailand, China, Malaysia MLM, Thailand, Vietnam and Indonesia) continued to show promising signs with revenue increasing by 41.9% to \$2.325m (2012: \$1.639m).

The Group's divisional result for 1st Half 2013 is summarised in the table below:

Half year ended 30 June	2013			2012		
	Health \$'000	Investment \$'000	Total \$'000	Health \$'000	Investment \$'000	Total \$'000
<b>Revenue</b>						
Sales to external customers	17,083	-	17,083	14,407	-	14,407
Total segment revenue	17,083	-	17,083	14,407	-	14,407
<b>Result</b>						
Segment results	2,763	(10)	2,753	1,396	(4)	1,392
Unallocated expenses			(163)			(221)
Profit before tax and finance costs			2,590			1,171
Finance costs			(52)			(72)
Profit before income tax			2,538			1,099
Income tax expense			(392)			(113)
<b>Net profit for the year</b>			<b>2,146</b>			<b>986</b>

**3. Net tangible assets**

	30 June 2013	30 June 2012
Net Tangible Assets per security	\$0.26	\$0.18

**4. Entities over which control has been gained or lost during the period**

**Control over entities**

Name of entity (or group of entities)

Not applicable

**Loss of control over entities**

Name of entity (or group of entities)

Not applicable

## 5. Dividends

A dividend of 0.5 cents per share fully franked amounting to \$274,000 was paid on 28 March 2013 in relation to the year ended 31 December 2012.

Directors have declared the payment of an interim dividend for the year ending 31 December 2013 of 1.0 cent per ordinary share franked to 41%, as disclosed at point 2.4 above.

## 6. Dividend Reinvestment plans

The Board of Directors have resolved to suspend the Company's DRP until further notice.

## 7. Details of associates and joint venture entities

	Place of Incorporation	Ownership Interest	
		30 June 2013	30 June 2012
		%	%
<b>Investment details</b>			
<b>Name of Company</b>			
<i>Unlisted</i>			
- Mitre Focus Sdn Bhd	Malaysia	6.3	6.3

## 8. Information on Audit or Review

This interim report is based on accounts to which one of the following applies

- The accounts have been subject to review
- The accounts are in the process of being subject to review
- The accounts have not yet been reviewed

**Description of likely dispute or qualification if the accounts have not yet been audited or subject to review or are in the process of being audited or subjected to review.**

Not applicable

## 9. For foreign entities, which accounting standards were used in compiling this report.

International Financial Reporting Standard - IFRS



## Half Year Report 30 June 2013



# Contents

<b>Directors' Report</b>	<b>1</b>
<b>Auditor's Independence Declaration</b>	<b>2</b>
<b>Condensed Consolidated Statement of Comprehensive Income</b>	<b>3</b>
<b>Condensed Consolidated Statement of Financial Position</b>	<b>4</b>
<b>Condensed Consolidated Statement of Cash Flow</b>	<b>5</b>
<b>Condensed Consolidated Statement of Changes in Equity</b>	<b>6</b>
<b>Notes to the Condensed Consolidated Financial Statements</b>	<b>8</b>
<b>Directors' Declaration</b>	<b>14</b>
<b>Independent Review Report</b>	<b>15</b>
<b>General Information</b>	<b>17</b>

---



## Directors' Report

The Directors of Vita Life Sciences Limited ("Company" or "Vita Life") submit their report together with the financial report for Vita Life and its controlled entities for the half year ended 30 June 2013.

### DIRECTORS

The names of the Company's directors in office throughout and since the end of the last financial period are set out below.

Mr Vanda R Gould	Non-executive chairman
Mr Eddie L S Tie	Managing director
Mr Henry G Townsing	Non-executive director
Mr Jonathan J Tooth	Non-executive director

All directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

### PRINCIPAL ACTIVITIES

During the period in review the principal continuing activities of the consolidated entity consisted of formulating, packaging, sales and distribution of vitamins and supplements and investment.

### OPERATING AND FINANCIAL REVIEW

#### Operating Results for the Half Year

For the reporting period the consolidated entity recorded a consolidated profit after tax attributable to members of \$2,136,000 (2012: \$993,000).

### ROUNDING OFF

The Company is of a kind referred to in ASIC Class Order 98/100 dated 10 July 1998 and in accordance with that Class Order, amounts in the financial report and Directors' report have been rounded off to the nearest thousand dollars, unless otherwise stated.

### AUDITOR'S INDEPENDENCE DECLARATION

The Directors have received an Independence Declaration from the external auditor, Russell Bedford NSW. A copy of this Declaration follows the Directors Report.

Signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

**Eddie L S Tie**  
Managing Director  
Sydney, 26 August 2013

# Auditor's Independence Declaration



**Russell Bedford**

New South Wales

Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000  
Australia

T: **+61 2 9032 3050**

F: +61 2 9032 3058

E: **mail@russellbedfordnsw.com.au**

W: **www.russellbedford.com.au**

26 August 2013

The Board of Directors  
Vita Life Sciences Limited  
Suite 650, Level 6  
1 Queens Road. St Kilda Towers  
MELBOURNE VIC 3004

## **LEAD AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001**

As lead auditor for the review of the financial statements of Vita Life Sciences Limited for the half year ended 30 June, 2013, I declare that, to the best of my knowledge and belief, there has been no contravention of:

- the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- contraventions of any applicable code of professional conduct in relation to the review.

RUSSELL BEDFORD NSW  
Chartered Accountants

A handwritten signature in black ink, appearing to read 'Gregory C. Ralph'.

Gregory C. Ralph, M.Com. FCA  
Partner



Member of Russell Bedford International – with affiliated offices worldwide  
Liability limited by a scheme approved under Professional Standards Legislation



# Condensed Consolidated Statement of Comprehensive Income

For the half year ended 30 June 2013

	Notes	2013 \$'000	2012 \$'000
<b>CONTINUING OPERATIONS</b>			
Sale of goods		17,083	14,407
Cost of sales		(5,621)	(5,238)
<b>Gross profit</b>		<b>11,462</b>	<b>9,169</b>
Other income		44	38
Distribution expenses		(1,461)	(1,256)
Marketing expenses		(1,014)	(1,080)
Occupancy expenses		(380)	(360)
Administrative expenses		(5,911)	(5,315)
Other expenses		(191)	(84)
Share of associates (loss) / profit		(7)	-
<b>Profit from continuing operations before interest and taxes</b>		<b>2,542</b>	<b>1,112</b>
Finance income		48	59
Finance costs		(52)	(72)
<b>Profit before income tax</b>		<b>2,538</b>	<b>1,099</b>
Income tax expense		(392)	(113)
<b>Net profit for the period</b>		<b>2,146</b>	<b>986</b>
<b>Other comprehensive income after income tax</b>			
Exchange differences on translating foreign controlled entities		762	(166)
Other comprehensive income for the period, net of income tax		762	(166)
<b>Total comprehensive income for the period</b>		<b>2,908</b>	<b>820</b>
Profit attributable to minority interest		10	(7)
Profit attributable to members of the parent		2,136	993
		2,146	986
Total comprehensive income / (expense) attributable to:			
Minority interest		17	(9)
Members of the parent		2,891	829
		2,908	820
<b>Earnings per share (cents per share)</b>			
- basic earnings per share	5	3.88	1.83
- diluted earnings per share	5	3.79	1.72

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying notes to the Half Year Report.

# Condensed Consolidated Statement of Financial Position

As at 30 June 2013

	Notes	30 June 2013 \$'000	31 December 2012 \$'000
<b>ASSETS</b>			
<b>Current Assets</b>			
Cash and cash equivalents		7,599	5,017
Trade and other receivables		4,764	4,481
Inventories		6,306	5,612
Other assets		421	469
<b>Total Current Assets</b>		<b>19,090</b>	<b>15,579</b>
<b>Non Current Assets</b>			
Investment in associates		1,044	947
Property, plant and equipment		253	126
Intangible assets		86	73
Deferred tax assets		120	88
<b>Total Non Current Assets</b>		<b>1,503</b>	<b>1,234</b>
<b>Total Assets</b>		<b>20,593</b>	<b>16,813</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
Trade and other payables		5,162	4,591
Current tax liability		547	289
Provisions		563	542
<b>Total Current Liabilities</b>		<b>6,272</b>	<b>5,422</b>
<b>Non Current Liabilities</b>			
Deferred Tax Liability		9	8
Provisions		35	41
<b>Total Non Current Liabilities</b>		<b>44</b>	<b>49</b>
<b>Total Liabilities</b>		<b>6,316</b>	<b>5,471</b>
<b>Net Assets</b>		<b>14,277</b>	<b>11,342</b>
<b>EQUITY</b>			
Issued capital	6	46,257	45,956
Accumulated losses		(31,670)	(33,532)
Employee share based payments reserve		472	472
Foreign currency translation reserve		(885)	(1,640)
<b>Parent entity interest</b>		<b>14,174</b>	<b>11,256</b>
Minority interest		103	86
<b>Total Equity</b>		<b>14,277</b>	<b>11,342</b>

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes to the Half Year Report.

# Condensed Consolidated Statement of Cash Flow

For the half year ended 30 June 2013

Notes	2013 \$'000	2012 \$'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Receipt from customers	18,723	15,034
Payments to suppliers and employees	(16,012)	(13,996)
Borrowing costs	(52)	(44)
Income tax paid	(169)	(130)
Interest received	48	59
<b>Net cash flows provided by operating activities</b>	<b>2,538</b>	<b>923</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Proceeds from sale of property, plant and equipment	-	22
Purchase of property, plant and equipment	(183)	(56)
Cash received upon acquisition of subsidiary	-	181
<b>Net cash flows (used in)/provided by investing activities</b>	<b>(183)</b>	<b>147</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Dividends Paid	(274)	(272)
Proceeds from loan repayment from LTIP	407	411
Shares bought back (net of costs)	(106)	(100)
Proceeds from issue of shares	-	31
<b>Net cash flows provided by financing activities</b>	<b>27</b>	<b>70</b>
Net increase in cash and cash equivalents	2,382	1,140
Net foreign exchange differences	200	32
Cash and cash equivalents at beginning of the period	5,017	3,632
<b>Cash and cash equivalents at end of the period</b>	<b>7,599</b>	<b>4,804</b>

The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the accompanying notes to the Half Year Report.

# Condensed Consolidated Statement of Changes in Equity

for the half year ended 30 June 2013



	Note	Issued Capital \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Minority Interests \$'000	Total \$'000
<b>Balance at 1 January 2013</b>		45,956	472	(33,532)	(1,640)	11,256	86	11,342
<b>Comprehensive income</b>								
Profit for the period		-	-	2,136	-	2,136	10	2,146
Other comprehensive income for the year		-	-	-	755	755	7	762
<b>Total comprehensive income for the period</b>		-	-	2,136	755	2,891	17	2,908
<b>Transactions with owners, in their capacity as owners</b>								
Shares bought back		(106)	-	-	-	(106)	-	(106)
Repayment of loans on Employee share option scheme		407	-	-	-	407	-	407
Dividends paid	7	-	-	(274)	-	(274)	-	(274)
<b>Total transactions with owners</b>		301	-	(274)	-	27	-	27
<b>Balance at 30 June 2013</b>		46,257	472	(31,670)	(885)	14,174	103	14,277

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes to the Half Year Report.



# Condensed Consolidated Statement of Changes in Equity

for the half year ended 30 June 2013 (Cont.)

	Note	Issued Capital \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Minority Interests \$'000	Total \$'000
<b>Balance at 1 January 2012</b>		45,568	272	(35,355)	(1,993)	8,492	464	8,956
<b>Comprehensive income</b>								
Profit attributable to members of parent entity		-	-	993	-	993	(7)	986
Other comprehensive income for the period		-	-	-	(164)	(164)	(2)	(166)
<b>Total comprehensive income for the period</b>		-	-	993	(164)	829	(9)	820
<b>Transactions with owners, in their capacity as owners</b>								
Issue of Shares (net of issue costs)		31	-	-	-	31	-	31
Recognition of non-controlling interest		-	-	-	-	-	87	87
Shares bought back		(100)	-	-	-	(100)	-	(100)
Repayment of loans on Employee share option scheme		411	-	-	-	411	-	411
Employee share option scheme		-	137	-	-	137	-	137
Dividends paid		-	-	(272)	-	(272)	-	(272)
<b>Total transactions with owners</b>		342	137	(272)	-	207	87	294
<b>Balance at 30 June 2012</b>		45,910	409	(34,634)	(2,157)	9,528	542	10,070

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes to the Half Year Report.

# Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2013

## 1. CORPORATE INFORMATION

The Half Year financial report of Vita Life Sciences Limited ("Vita Life") and its controlled entities ("the Group") for the half year ended 30 June 2013 was authorised for issue by a resolution of the directors on the date of this report.

Vita Life is a Company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange ("ASX").

The nature of the operations and principal activities of the Group are described in the Director's Report.

## 2. BASIS OF PREPARATION

These general-purpose condensed consolidated financial statements for the half-year reporting period ended 30 June 2013, have been prepared in accordance with the requirements of the *Corporations Act 2001*, and Australian Accounting Standard AASB 134 "Interim Financial Reporting." The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Vita Life Sciences Limited. As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2012, together with any public announcements made during the following half-year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

The half-yearly condensed consolidated financial statements have been prepared on a historical cost basis.

For the half-year reporting period to 30 June 2013, a number of new and revised Accounting Standard requirements became mandatory for the first time, and several were applicable to the Group. None of these have affect the Group's accounting policies or the amounts reported in the financial statements.

A short description of the new and amending Standards that became applicable to the Group for the first time during this half-year reporting period are as follows:

- *AASB 10 Consolidated financial statements:*

AASB 10 provides a revised definition of control and additional guidance so that a single control model will apply to all investees. Revised AASB 127 facilitates the application of AASB 10: the assets, liabilities and non-controlling interests related to investments in businesses that are now assessed as being controlled by the Group, and were therefore not previously consolidated, are measured as if the investee had been consolidated (and therefore applied acquisition accounting in accordance with AASB 3: Business Combinations) from the date when the Group obtained control of the investee on the basis of the requirements in AASB 10. This change did not affect the Group's accounting policies or the amounts reported in the financial statements.

# Notes to the Condensed Consolidated Financial Statements (continued)

## 2. BASIS OF PREPARATION (CONT.)

- AASB 13: *Fair Value Measurement* and AASB 2011-8: *Amendments to Australian Accounting Standards arising from AASB 13*.

These Standards are mandatorily applicable from 1 January 2013 and thus, become applicable to the Group for the first time in the current half-year reporting period. AASB 13 sets out a comprehensive framework for measuring the fair value of assets and liabilities and prescribes enhanced disclosures regarding all assets and liabilities measured at fair value. These Standards did not affect the Group's accounting policies or the amounts reported in the financial statements.

- AASB 2012-2: *Amendments to Australian Accounting Standards – Disclosures – Offsetting Financial Assets and Financial Liabilities* and AASB 2012-5: *Amendments to Australian Accounting Standards arising from Annual Improvements 2009-2011 Cycle*.

These Standards make changes to presentation and disclosure requirements, but did not affect the Group's accounting policies or the amounts reported in the financial statements.

## 3. SEGMENT REPORTING

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Total \$'000
<b>Half year ended 30 June 2013</b>					
<b>Revenue</b>					
Sales to external customers	6,925	2,741	5,945	1,472	17,083
<b>Segment results</b>					
Profit / (loss) before tax and finance costs	804	967	997	(171)	2,597
Finance costs	(24)	(1)	(25)	(2)	(52)
Share of profit of associates				(7)	(7)
Profit before income tax					2,538
Income tax expense					(392)
<b>Net profit for the period</b>					<b>2,146</b>
<b>Assets and liabilities</b>					
Segment assets	7,745	2,770	6,590	2,444	19,549
Investment in associates					1,044
Total assets					20,593
Segment liabilities	2,626	851	2,680	159	6,316
Total liabilities					6,316
<b>Other segment information</b>					
Capital expenditure	(7)	(61)	(89)	(26)	(183)
Depreciation	(3)	(17)	(13)	(4)	(37)
Amortisation	-	(5)	(1)	(1)	(7)

# Notes to the Condensed Consolidated Financial Statements (continued)

## 3. SEGMENT REPORTING (CONT.)

	Australia \$	Singapore \$	Malaysia \$	Others \$	Total \$
<b>Half year ended 30 June 2012</b>					
<b>Revenue</b>					
Sales to external customers	6,629	2,118	4,814	846	14,407
<b>Segment results</b>					
Profit / (loss) before tax and finance costs	705	377	536	(447)	1,171
Finance costs	(44)	(1)	(25)	(2)	(72)
Share of profit of associates	-	-	1	(1)	-
Profit before income tax					1,099
Income tax expense					(113)
<b>Net profit for the period</b>					<b>986</b>
<b>Assets and liabilities</b>					
Segment assets	7,388	1,632	3,878	1,653	14,551
Investment in associates					929
Unallocated assets					
Total assets					15,480
Segment liabilities	2,773	899	1,611	127	5,410
Total liabilities					5,410
<b>Other segment information</b>					
Capital expenditure	(7)	(10)	(17)	(22)	(56)
Depreciation	(2)	(14)	(19)	(8)	(43)
Amortisation	-	(4)	(1)	(1)	(6)



# Notes to the Condensed Consolidated Financial Statements (continued)

## 4. NET TANGIBLE ASSETS

	30 June 2013 \$	31 Dec 2012 \$
Net assets per share	0.26	0.20
Net tangible assets per share	0.26	0.20
	Number	Number
Weighted average number of ordinary shares for net assets per share	55,013,690	56,474,638

## 5. EARNINGS PER SHARE

	30 June 2013 \$'000	30 June 2012 \$'000
<b>(a) Earnings used in calculating earnings per share</b>		
Net profit attributable to equity holders from continuing operations	2,146	986
(Profit) / Loss attributable to minority interest	(10)	7
Net profit attributable to equity holders of the parent used to calculate EPS	<b>2,136</b>	<b>993</b>
	Number	Number
<b>(b) Weighted average number of shares</b>		
Weighted average number of ordinary shares for basic earnings per share	55,013,690	54,184,724
Adjusted weighted average number of ordinary shares for diluted earnings per share	56,426,190	57,788,474

# Notes to the Condensed Consolidated Financial Statements (continued)

## 6. CONTRIBUTED EQUITY

	30 June 2013	30 June 2012	30 June 2013	30 June 2012
	Number	Number	\$	\$
<b>Issued and paid up capital</b>				
Ordinary shares	<b>56,369,295</b>	<b>57,653,508</b>	<b>46,256,952</b>	<b>45,909,529</b>
<b>Ordinary shares</b>				
Balance at beginning of the financial period	56,474,638	57,845,060	45,956,146	45,568,037
Share buy back (a)	(105,343)	(294,931)	(105,994)	(99,659)
Shares issued during the financial period	-	103,379	-	30,551
Cancellation of Plan Shares of certain employees and Director	-	(325,000)	-	-
Issue of shares to employee / director	-	325,000	-	-
Plan shares exercised (b)	-	-	406,800	410,600
Balance at end of the financial period	<b>56,369,295</b>	<b>57,653,508</b>	<b>46,256,952</b>	<b>45,909,529</b>

- a) A total of 105,343 ordinary shares were bought back in the period ended 30 June 2013 as approved by the shareholders in the 16 May 2012 and 23 May 2013 Annual General Meetings at a total cost of \$105,994.
- b) During the period ended 30 June 2013, a sum of \$406,800 was paid by the Managing Director and employees of the Group to retire limited recourse loans for a total of 1,695,000 ordinary shares issued under the Company's Long Term Incentive Plan in 2011.

## 7. DIVIDEND

A dividend of 0.5 cents per share fully franked amounting to \$274,000 (2012: 0.5 cents per share fully franked totalling \$272,000) was paid on 28 March 2013 in relation to the year ended 31 December 2012.

An interim dividend of 1.0 cents per share franked to 41% has been declared and will be paid on 29 September 2013. The record date for the interim dividend is 22 September 2013.

## 8. COMMITMENTS

There are no significant changes to the commitments as previously disclosed in the Annual Report for the financial year ended 31 December 2012.

## 9. EVENTS AFTER THE BALANCE SHEET DATE

Other than those mentioned in the financial statements and notes thereto, no matters or circumstances have arisen since the end of the financial period which significantly affected or could significantly affect the operations of the economic entity, the results of those operations or the state of affairs of the economic entity in future financial years.

## 10. CONTINGENT ASSETS AND LIABILITIES

The Group has no contingent assets or liabilities as at 30 June 2013.

# Notes to the Condensed Consolidated Financial Statements (continued)

## 11. RELATED PARTIES DISCLOSURES

### Transactions with related parties

The following table provides the total amount of transactions that were entered into with related parties for the relevant financial period.

	CONSOLIDATED	
	30 June 2013	30 June 2012
	\$	\$
<b>Other transactions with related parties</b>		
Business Intelligence & Support Inc. (i)	292,140	233,846
CVC Venture Managers Pty Ltd (ii)	50,091	55,102
Pilmora Pty Ltd (iii)	7,500	7,500
Melbourne Corporation Pty Ltd (iv)	15,975	-
	<b>365,706</b>	<b>296,448</b>

- (i) Business Intelligence & Support Inc., a company in which Mr Eddie Tie is a director, and therefore a related party, provided international business advisory, sales, marketing and promotion services to the Group. \$51,894 remained payable as at 30 June 2013, and is disclosed in trade and other payables.
- (ii) CVC Venture Managers Pty Limited, a company in which Mr Vanda Gould and Mr Henry Townsing are directors, was paid consultancy fees during the financial period. There was no amount payable as at 30 June 2013.
- (iii) Pilmora Pty Ltd, a company in which Mr Henry Townsing is a director was paid a consultancy fee during the financial period. There was no amount payable as at 30 June 2013.
- (iv) Melbourne Corporation Pty Ltd, a company in which Mr Vanda Gould is a director, provided company secretarial services to the Group for which it was paid a fee during the financial period. There was no amount payable as at 30 June 2013.

## Directors' Declaration

In the opinion of the directors of Vita Life Sciences Limited:

1. (a) The financial statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001*, including:
  - (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2013 and its performance for the half-year ended on that date; and
  - (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting*, Corporations Regulations 2001 and other mandatory professional reporting requirements.
- (b) There are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the Corporations Act 2001:



**Eddie L S Tie**

Managing Director

Sydney, 26 August 2013

# Independent Review Report



**Russell Bedford**  
New South Wales

Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000  
Australia

T: **+61 2 9032 3050**  
F: +61 2 9032 3058  
E: [mail@russellbedfordnsw.com.au](mailto:mail@russellbedfordnsw.com.au)  
W: [www.russellbedford.com.au](http://www.russellbedford.com.au)

## **Independent Review Report To the members of Vita Life Sciences Limited**

### **Report on the Half-Year Financial Report**

We have reviewed the accompanying half-year financial report of Vita Life Sciences Limited and the entities it controlled during the period which comprises the condensed consolidated statement of financial position as at 30 June 2013, the condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity, condensed consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

### **Directors Responsibility on the Half-Year Financial Report**

The directors of Vita Life Sciences Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of an Interim Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the company's financial position as at 30 June 2013 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As auditor of Vita Life Sciences Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Our review did not involve an analysis of the prudence of business decisions made by directors or management.



Member of Russell Bedford International – with affiliated offices worldwide  
Liability limited by a scheme approved under Professional Standards Legislation

## **Matters Relating to Electronic Publication of the Reviewed Financial Report**

This review report relates to the financial report of Vita Life Sciences Limited for the half year period ended 30 June 2013 included on the website of Vita Life Sciences Limited. The directors of the company are responsible for the integrity of the website and we have not been engaged to report on this integrity. This review report refers only to the subject matter described above. It does not provide an opinion on any other information which may have been hyperlinked to or from the financial report. If users of the financial report are concerned with the inherent risk arising from publication on a website, they are advised to refer to the hard copy of the reviewed financial report to confirm the information contained in this website version of the financial report.

## **Independence**

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

## **Conclusion**

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Vita Life Sciences Limited and the entities it controlled during the period is not in accordance with the Corporations Act 2001 including:

- a) giving a true and fair view of the consolidated entities financial position as at 30 June 2013 and of its performance for the half-year ended on that date; and
- b) complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

RUSSELL BEDFORD NSW  
Chartered Accountants



Gregory C. Ralph M.Com. FCA  
Partner

Sydney, 26 August 2013



Member of Russell Bedford International – with affiliated offices worldwide  
Liability limited by a scheme approved under Professional Standards Legislation

# General Information

## Board of Directors

### Vanda Gould

Non-Executive Chairman

### Eddie L S Tie

Managing Director

### Jonathan Tooth

Non-Executive Director

### Henry Townsing

Non-Executive Director

## Company Secretary

Ernest Chunge

## Corporate Office

Suite 650, Level 6  
1 Queens Road  
Melbourne VIC 3004  
T: 61 (03) 9828 0500  
F: 61 (03) 9820 5957

## Australian Regional Office

Unit 1/ 102, Bath Road  
Kirrawee  
NSW 2232  
T: 61 (02) 9545 2633  
F: 61 (02) 9545 1311

## Asian Regional Office

81G, Jalan SS 21/60  
Damansara Utama  
47400 Petaling Jaya  
Malaysia  
T: 60 (03) 7729 3873  
F: 60 (03) 7727 4658

## Securities Exchange Listing

The ordinary shares of Vita Life Sciences Limited are listed on the Australian Securities Exchange Ltd (code: VSC).

## Auditor

Russell Bedford NSW  
Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000

## Banker

Westpac Banking Corporation

National Australia Bank Limited

## Solicitor

Steven Kunstler

## Share Registry

Gould Ralph Pty Ltd  
Level 42, Suncorp Place  
259 George Street  
Sydney NSW 2000  
T: 61 (02) 9032 3000  
F: 61 (02) 9032 3088

## *Change of Address*

Shareholders who have changed address should advise our share registry in writing.

## *Annual Report Mailing*

Shareholders who do not want the annual report or who are receiving more than one copy should advise the share registry in writing.

## Vita Life Website

Vita Life has a website containing information about the Company, its Business and Products.

[www.vitalifesciences.com.au](http://www.vitalifesciences.com.au)

VLS